Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago.



Enrollment is ongoing in ASCEND (NCT07335497), a global, open-label Phase 1/2 clinical trial evaluating CR-001 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and various gastrointestinal and gynecological cancers, in both treatment-naïve and previously treated patients. The trial is expected to enroll up to 290 patients in dose-escalation, backfill and dose-optimization cohorts at centers across multiple regions, including the United States, Europe and Asia Pacific. The primary objectives of the study are to evaluate the safety and tolerability of CR-001. Secondary objectives include the assessment of pharmacokinetic and pharmacodynamic profiles, identification of the recommended Phase 2 dose, and evaluation of preliminary antitumor activity, including overall response rate (ORR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS).

"CR-001 is designed to serve as an immuno-oncology backbone and best-in-class PD-1 x VEGF bispecific antibody for people living with cancer," said Ellie Im, M.D., chief medical officer of Crescent. "We are encouraged by the strong global engagement from investigators involved in ASCEND, which underscores both the unmet need in cancer treatment and the study's efficient design to evaluate CR-001 as a monotherapy and in combination with standard-of-care therapies. Together with our planned ADC combination studies, this development strategy is intended to rapidly expand our understanding of CR-001 across multiple solid tumor types, beginning with initial ASCEND data expected in the first quarter of 2027."